Stakeholder Communication Flashcards

During a Pre-IND meeting with the FDA, what is the most important communication objective for the regulatory affairs team?

Answer: To clearly present the proposed development program and obtain agency guidance on key scientific and regulatory questions

Pre-IND meetings aim to present the proposed development program and obtain FDA guidance on critical questions to inform the IND strategy and reduce development risk.

Which of the following is a best practice for managing communications with multiple regulatory agencies simultaneously during a global submission?

Answer: Use a centralized tracking system and tailor communications to each agency's regional requirements and formats

Global submissions require centralized tracking and agency-specific tailoring because regulatory requirements, formats, and expectations vary significantly across regions.

A patient advocacy group requests a briefing on the regulatory status of a product they are following. What should a regulatory affairs professional consider before responding?

Answer: What information is publicly available versus confidential, and what level of detail is appropriate for the audience

Communications with patient advocacy groups must balance transparency with confidentiality obligations and be tailored to the lay audience's level of understanding.

In post-market surveillance, how should regulatory affairs communicate emerging safety data to clinical and medical affairs teams?

Answer: Communicate significant new safety findings promptly, with context on regulatory reporting obligations and required actions

Timely communication of significant safety signals, including regulatory reporting obligations and required actions, enables the organization to respond appropriately and meet compliance requirements.

What is the primary risk of using email for all regulatory agency communications?

Answer: Email may lack the formality, traceability, or security required for certain regulatory submissions and official correspondence

Email may not meet the formal documentation, traceability, or security requirements for official regulatory submissions and correspondence, which often require agency-specified portals or formats.

When a regulatory affairs professional disagrees with a proposed regulatory strategy championed by a senior colleague, what is the most appropriate communication approach?

Answer: Raise concerns through appropriate channels, providing evidence-based rationale in a constructive and professional manner

Professional disagreement in regulatory strategy should be expressed constructively and evidence-based through appropriate channels, ensuring scientific integrity without creating unnecessary conflict.

A regulatory affairs professional must communicate a manufacturing change and its regulatory impact to a quality assurance team. What should be the focus of the communication?

Answer: The regulatory pathway required (e.g., PAS, CBE-30, CBE-0, AR) and the documentation and timeline implications for QA

QA teams need specific regulatory pathway information, documentation requirements, and timeline implications to properly manage manufacturing change submissions.